



NATIONWIDE INCIDENCE RATE

1 IN 8 MEN
will be diagnosed with
prostate cancer in their lifetime

3.3+ MILLION MEN
currently diagnosed with prostate cancer

This year in the United States:
New cases: **299,010** | Deaths: **35,250**

VETERANS ARE 1.5X
more likely to get prostate cancer

AFRICAN AMERICAN MEN ARE 2.1X
more likely to die of prostate cancer.

INCIDENCE RATE IN NEW YORK

130.3 IN EVERY 100,000 MEN
will be diagnosed with
prostate cancer in their lifetime

16.2 IN EVERY 100,000 MEN
die from the disease

This year in New York:
New cases: **20,630** | Deaths: **1,630**

NATIONAL RANKINGS BY STATE:

#9 for prostate cancer incidence
#51 for prostate cancer deaths

Source: Estimates based on 2024 data from the American Cancer Society

ZERO's Impact in New York

Patient Programs

- **ZERO360** is a free, comprehensive support service that helps patients and their loved ones navigate insurance, find resources to help pay for treatment and living expenses, connect with emotional support services, and ensure access to care.
- **ZERO's nationwide Us TOO support group network** offers a variety of peer-led virtual and in-person groups offering emotional support, resources, and education to empower those impacted by prostate cancer to make informed decisions about their care.
- **ZERO's MENtor program** matches patients with trained, volunteer MENtors who have been on a similar journey to provide ongoing, one-on-one support.
- **ZERO Connect** is our online private Facebook group where you can connect with others affected by prostate cancer, ask questions, and learn from their experiences.

CDMRP* Grants in New York

Year Introduced: 1997

Total Grants to Date: 371

Total Grand Awards Through FY 2022:** \$235.2M

* Congressionally Directed Medical Research Programs

**PCRP (Prostate Cancer Research Program) data for FY 2023 has not yet been posted

GRANT RECIPIENT	YEAR	AMOUNT
Health Research Inc Roswell Park Division	2002	\$14,135,890
Sloan Kettering Institute For Cancer Research	2017	\$8,198,332
	2014	\$7,330,349
	2012	\$6,984,950
	2008	\$11,303,943

CDC's National Comprehensive Cancer Control Program (NCCCP) Funding in New York:

- **According to the CDC**, general population screening for certain cancers (e.g., prostate, skin, or ovarian cancers) has not been proven successful in lowering cancer-related deaths. Individuals should understand their personal risk factors and family histories and speak with health care providers about screening options. Symptom recognition and prompt follow-up can also be of benefit in detecting cancer in earlier stages (e.g. ovarian cancer). Given the uncertain benefits of population-based screening for certain cancers in average-risk individuals, individuals should make informed decisions about screening with their health care providers.
- **Objective:** By 2017, reduce barriers to screenings and diagnostic services for disparate populations so that there are no significant differences in screening rates and rates of invasive or late stage diagnosis by race, ethnicity, income level, education level, insurance status or geographic location.

New York law requires the coverage of prostate cancer screening without cost sharing for all men over age 40 with a family history of prostate cancer and all men over age 50.

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. Visit our website: www.zerocancer.org.

ZERO Contact:

Ali Manson, MPH
 Vice President, Government Relations & Advocacy
ali@zerocancer.org | 703-624-1223



ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator and is accredited by the Better Business Bureau.